Replies to post #209486 on Biotech Values

[dangerM]

DVAX fully irrational gain ...

... given the "no substantial news" character of the NDA acceptance, I can only explain today's move with a probably still high short interest of over 20 pct (8.5mn/39mn)*, probably even higher if calculated on the float or non-institutional investors share.

The actual news should come this evening with AACR abstracts**, but judging from the titles they are what one would expected (i.e. IMHO nothing that would justify a 50pct share price jump).

So I realized losses on half of my position based on the "sell on good news that are no news" principle.


*http://www.nasdaq.com/symbol/dvax/short-interest - 2/15/2017: 8,445,486


**

Session PO.IM02.11 - Enzymes and Hormones and Metabolism in Tumor Immunity
5596 / 28 - Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration

www.abstractsonline.com/pp8/#!/4292/presentation/6385

and

Session PO.CL06.01 - Immunomodulatory Agents and Therapeutics
4696 / 12 - Development of an inhaled TLR9 agonist for the immunotherapy of lung cancer

www.abstractsonline.com/pp8/#!/4292/presentation/6078

[DewDiligence]

DVAX +8% on Heplisav briefing docs for upcoming advisory panel:

https://t.co/y0nY30oLwL